• N&PD Moderators: Skorpio | thegreenhand

MSP-1014: “next-generation psychedelic”?

Addam

Bluelighter
Joined
Aug 23, 2010
Messages
239
Just saw this article
https://www.globenewswire.com/news-...4-a-Next-Generation-Psychedelic-Medicine.html
Talks about Mindset Pharma’s “next-generation” psychedelic; according to them, it is superior to psilocybin and psilocin.
But what I’m curious about is its chemical structure. I did the briefest of scans of the internet but figured I’d come here and be lazy, hoping someone here might know something about what this chemical looks like.
Anybody have anything beyond speculation? They do say it’s psilocybin-derived…
I’m gonna go back to digging for information…
 
"The superiority to psilocybin is due in part to the incorporation of a conjugated amplification moiety (CAM) that enhances 5-HT2A specific effects while reducing non-specific effects. In addition, the manufacturing process of MSP-1014 precludes the phosphorylation step, one of the most challenging chemical synthesis steps in psilocybin manufacturing."

Hard to say if it will be better or nearly as good. They are very vague with the effects.

It could be a brand new next gen psychedelic, or it might be a shitty version of mushrooms like marinol was to cannabis.

That 2nd paragraph makes me think this is just some ploy for investors because there's a lot of rich people looking to patent psychedelic medicine.

Hard to tell, but the definitely use a lot of corporate jargon in this article.

Of course they're going to claim "superiority" when they're trying to sell it. This is all basic info coming from lab rats.
 
Of course, but I’m still very interested in seeing what this thing looks like and just how full of shit these people might be 😁
 
i Doubt that idiot even knows what precludes mean. Makes impossible the phosphorylation step? lol what? this fucking is a scam straight up
 
also these dudes have no degree or education from anywhere and were once running scam casino game companies lol
 
"The superiority to psilocybin is due in part to the incorporation of a conjugated amplification moiety (CAM) that enhances 5-HT2A specific effects while reducing non-specific effects. In addition, the manufacturing process of MSP-1014 precludes the phosphorylation step, one of the most challenging chemical synthesis steps in psilocybin manufacturing."

Hard to say if it will be better or nearly as good. They are very vague with the effects.

It could be a brand new next gen psychedelic, or it might be a shitty version of mushrooms like marinol was to cannabis.

That 2nd paragraph makes me think this is just some ploy for investors because there's a lot of rich people looking to patent psychedelic medicine.

Hard to tell, but the definitely use a lot of corporate jargon in this article.

Of course they're going to claim "superiority" when they're trying to sell it. This is all basic info coming from lab rats.
The phosphorylation step is not necessary. Psilocybin gets dephosphorylated in vivo to psilocin to become active.

Realisticly I would bet on @TripSitterNZ being corrext. I have some hope that they have found some constrained scaffold that sheds light on tryptamine sar, but that's a pipe dream honestly. Also unsure that a more 5ht2a selective tryptamine would even be an improvement.
 
I couldn't find the patents, I guess they don't get posted online when they're still pending. I'm curious to find out what the hell a "conjugated amplification moiety" is.
 
So it's a selective 5-HT2A agonist?

What exactly makes that any different from NBOMes?
 
I couldn't find the patents, I guess they don't get posted online when they're still pending. I'm curious to find out what the hell a "conjugated amplification moiety" is.
a conjugated amplification moiety is a bullshit structure for extracting funds from gullible investors.

All of these new psychedelic companies are solely about money extraction. They are trying to fence off the collective psychedelic commons to personally profit.

The Mindset Pharma main pitch is based on them having an improved synthesis of psilocin which they are in the process of patenting just like all the other similar companies (Compass Atai etc etc). The patent may be granted because the USPTO doesn't care so long as the fees are paid, but that doesn't mean it is valid or enforceable, With something as simple as psilocin synthesis it is trivial for a competitor to circumvent or improve on it it. Ultimately making a patent pointless and the only purpose of filing patents is to give a positive news spin to investors.

Any representative of any organisation who wants to bust open and destroy any particular psychedelic patent, feel free to message me, I will give you the prior art, the tools and information you need for free.

The whole field is shady even by pharma standards. Investors: only Invest if you believe a bag-holder dumber than you is going to appear before you need to get out. Remember what happened with corporate commercial cannabis, boom followed by oversupply and collapse. Here we have the same characters, the business same model and the same ultimate outcome is inevitable, be warned.
 
Reading this I got the impression they were just trying to make a easier to manufacture prodrug for psilocin than psilocybin.

The phosphorylation step would be in the manufacturing process not the metabolic process. Psilocin is really unstable and psilocybin is hard to manufacture so they made whatever this is they made.

It will just metabolize into psilocin however. Is what I gathered reading, I think the writer sucked.
 
So what is the IUPAC name? I didn't see it but am very intinterested. I hope it's not unlike just 4-pro-dmt or something similar. I'd like to see more on the actual structure....
 
Top